Compare MXCT & DH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MXCT | DH |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.2M | 112.1M |
| IPO Year | 2021 | 2021 |
| Metric | MXCT | DH |
|---|---|---|
| Price | $1.10 | $0.93 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 7 |
| Target Price | ★ $4.11 | $1.90 |
| AVG Volume (30 Days) | 325.0K | ★ 1.1M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.28 |
| EPS | ★ N/A | N/A |
| Revenue | $33,026,000.00 | ★ $241,521,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $0.61 |
| 52 Week High | $1.86 | $3.49 |
| Indicator | MXCT | DH |
|---|---|---|
| Relative Strength Index (RSI) | 41.47 | 50.43 |
| Support Level | $1.11 | $0.90 |
| Resistance Level | $1.16 | $0.94 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 15.38 | 20.57 |
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.